Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management

Moigne, M. Le; Saint‐Jean, M.; Jirka, A.; Quéreux, G.; Peuvrel, L.; Brocard, Anabelle; Gaultier, Aurélie; Khammari, Amir; Dréno, Brigitte

doi:10.1007/s00520-015-2932-1

Cited by 13 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,16,17 Nutritional management has been suggested to mitigate weight loss and malnutrition in patients treated with HHIs. 33…”

Section: Alopeciamentioning

confidence: 99%

A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

Migden¹,

Farberg²,

Dummer³

et al. 2021

JDD

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common malignancy in fair-skinned populations. Most cases are successfully treated with surgery, but in advanced BCC-including locally advanced BCC and metastatic BCC-surgery is likely to result in substantial morbidity or unlikely to be effective. In those patients, the systemic Hedgehog inhibitors (HHIs) sonidegib and vismodegib are the only approved pharmacologic treatment option. Although a number of clinical studies highlight the similarities and differences between the two HHIs, no head-to-head clinical comparison is available. Results from the pivotal BOLT and ERIVANCE clinical studies for sonidegib and vismodegib, respectively, demonstrate similar efficacy measured by objective response rate, complete response rate, and histologic tumor subtype. Safety results for both studies are comparable with similar common adverse events reported for muscle spasms, alopecia, and dysgeusia. A notable difference between sonidegib and vismodegib is their respective pharmacokinetic profiles with sonidegib reaching peak concentration in plasma within 2-4 hours of dosing and steady state in plasma achieved by week 17 of treatment, while vismodegib reaches peak plasma concentration approximately 2 days after a single dose and steady state within 21 days of repeated dosing. This review compares efficacy, safety, and pharmacokinetics of sonidegib and vismodegib based on published literature to date.

show abstract

“…12,16,17 Nutritional management has been suggested to mitigate weight loss and malnutrition in patients treated with HHIs. 33…”

Section: Alopeciamentioning

confidence: 99%

A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

Migden¹,

Farberg²,

Dummer³

et al. 2021

JDD

View full text Add to dashboard Cite

show abstract

“…Significantly, a greater than 5% weight loss can occur without dysgeusia, possibly due to diarrhea, nausea, xerostomia, oral thrush, or abdominal pain. 4 Addressing oral hygiene, reflux disease, low-grade oral infection, and postnasal drip are reported to improve taste sensation in non-HPI patients. 3 While patients who undergo HPI therapy are generally older adults, premenopausal women of childbearing age may experience amenorrhea likely due to reversible follicle-stimulating hormone receptor inhibition.…”

Section: Practical Management Of the Adverse Effects Of Hedgehog Pathway Inhibitor Therapy For Basal Cell Carcinomamentioning

confidence: 99%

Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma

Jacobsen

Kydd

Strasswimmer

2017

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…The recommended management algorithm is presented in Figure 2B. Access to a nutritionist or dietitian at baseline and throughout treatment is beneficial [57], and the patient should be reminded to maintain adequate caloric intake and hydration. Dietary counseling has resulted in reduction in the occurrence of both early-onset and long-term dysgeusia.…”

Section: Introductionmentioning

confidence: 99%

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Dréno²,

et al. 2016

Self Cite

View full text Add to dashboard Cite

Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article.

show abstract

Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management

Abstract: The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.

Cited by 13 publications

References 19 publications

A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Contact Info

Product

Resources

About